Prospector
Profile
222-04
|
| |
| MediCor Limited |
NAICS |
339113 |
| 4560 South Decatur Boulevard, Suite 300
North Las Vegas, NV 89031 |
Description |
Surgical Equipment Mfg. |
| (702) 932-4560 |
Employees |
410 |
| http://www.medicorltd.com/ |
Revenue |
(mil) |
129.1200 |
| |
Income |
(mil) |
119.1600 |
| |
Assets |
(mil) |
31.3800 |
| |
Liability |
(mil) |
17.9500 |
| |
(for the year ended 2006-06-30) |
| |
|
Category:
Miscellaneous
|
| |
|
Event:
MediCor Ltd. and its debtor-affiliates said in court filings that an interested purchaser has resurfaced and wants to continue talks to purchase all the Debtors' European assets, while implementing a plan to revamp their European affiliates' management team. The European affiliates are:
-- Eurosilicone SAS;
-- Biosil Ltd.; and
-- Nagor Ltd.
According to the Debtors, the negotiation has resulted in agreements in principle for the sale of all of the issued and outstanding shares of the European affiliates, including the purchase of the remaining assets of MediCor Development Company. Victoria W. Counihan, Esq., at Greenberg Traurig LLP, says that the Debtors expect that the agreements will be completed shortly and that the appropriate motions for approval will be filed with the United States Bankruptcy Court for the District of Delaware.
|
| |
|
Intellectual Property:
The Company currently owns or has exclusive license rights to numerous patents, patent applications, trademarks and trademark applications throughout the world. The Company requires that all employees and consultants execute a proprietary information and inventions agreement relating to its proprietary information and intellectual property rights. The Company's trademarks cover a large percentage of its commercial products. The current commercial breast implant line is manufactured and distributed completely outside the United States and the design technology and manufacturing technology are considered trade secrets. U.S. patents to which the Company acquired ownership and the corresponding foreign patents protect technology in the research and development of a new generation of breast implant fillers, shell material and component design. Another patent protects a minor product in its dermatology and wound care offerings. [SEC Filing 10-KSB 09-28-2006]
|
| |
|
Description:
The Company acquires, develops, manufactures and markets products primarily for aesthetic, plastic and reconstructive surgery and dermatology markets. MediCor and its debtor-affiliates filed for Chapter 11 protection on June 29, 2007, with the U.S. Bankruptcy Court for the District of Delaware, lead case number 07-10877, before Judge Mary F. Walrath.
|
| |
|
Officers:
Donald K. McGhan (Chair); Theodore R. Maloney (CEO); Paul R. Kimmel (CFO); Jim J. McGhan (Dir.); Mark E. Brown (Dir.); Samuel C. Rogers (Dir.); Thomas Y. Hartley (Dir.); Robert L. Forbuss (Dir.); Ikram U. Khan (Dir.); Eugene I. Davis (Dir.)
|
| |
|
Auditor:
Greenberg & Company LLC
|
| |
|
Attorneys:
Victoria Watson Counihan, Esq., at Greenberg Traurig LLP; Wilmington, DE; (302) 661-7000
|
| |
|
Securities:
Common Stock Symbol MDCR.PK; Other OTC;
23,746,162 common shares outstanding as of September 26, 2006.
|
| |
| |
| |
| return to main page |
